AMGN240628P270000
- 0.18
- 0.000.00%
Amgen Newsroom
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June's sharply lower-than-expected services sector activ
Express News | Amgen received commercialization rights for Avacopan in Asia and the Americas.
What the Options Market Tells Us About Amgen
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 9 unusual trades.Delving into the details, we found 11% of traders were
Alvotech Says Study on Proposed Biosimilar to Prolia, Xgeva Meets Primary Endpoints
Alvotech (ALVO) said Tuesday a confirmatory study for AVT03, a proposed biosimilar to Amgen's (AMGN) denosumab sold as Prolia and Xgeva, met its primary endpoints. The study aims to show clinical simi
Amgen Unusual Options Activity
Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen.Looking at options history for Amgen (NASDAQ:AMGN) we detected 10 trades.If we consider the specifics of each trade,
Watch Now: ETF Edge on Reshoring Trends, Weight Loss Drugs and More
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Amgen Is Maintained at Buy by Argus Research
Amgen Is Maintained at Buy by Argus Research
Argus Research Maintains Buy on Amgen, Raises Price Target to $340
Argus Research analyst David Toung maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $300 to $340.
Amgen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 8.83% Argus Research $300 → $340 Maintains Buy 06/14/2024 6.27% RBC Capital $328 → $332 Maintai
Argus Research Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $340
Argus Research analyst Jasper Hellweg maintains $Amgen(AMGN.US)$ with a buy rating, and adjusts the target price from $310 to $340.According to TipRanks data, the analyst has a success rate of 60.5% a
Novo Nordisk, Eli Lilly Still Top 2 Pharma Stocks: Analyst
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China.
Novo-Nordisk's "miracle weight-loss drug" has been approved domestically, waiting to explode onto the multi-billion dollar market! How to capture this wave of "weight-loss fever"?
With the relentless competition among pharmaceutical research and development companies, the indications for GLP-1 are expected to continuously expand, and institutions are also constantly revising their expectations for the market size of weight-loss drugs.
US stocks dig gold | The two giants of weight-loss drugs have refreshed their heights! Novo Nordisk's weight-loss drug has been approved for sale in China; performance has ignited stock prices! Carnival Cruise Line soared nearly 9% after the results.
Medical global sectors are rebounding! Intuitive Surgical rose more than 3%, up more than 30% this year, with an average annual ROI of 24% over the past 15 years. Alnylam Pharmaceuticals rose nearly 8%, up more than 55% in the past four trading days, and positive phase 3 data for new drugs is still fermenting. Regeneron Pharmaceuticals rose nearly 1%, up more than 20% this year, with RBC Capital Markets analyst maintaining a target price of $1229 per share.
The Zacks Analyst Blog Highlights Chevron, Amgen, Philip Morris, Hurco and Perma-Pipe
Why Amgen (AMGN) Outpaced the Stock Market Today
Top Stock Reports for Chevron, Amgen & Philip Morris
Smart Money Is Betting Big In AMGN Options
Investors with a lot of money to spend have taken a bearish stance on Amgen (NASDAQ:AMGN).And retail traders should know.We noticed this today when the trades showed up on publicly available options h
Amgen on Track for Record High Close -- Data Talk
Amgen Inc. (AMGN) is currently at $325.55, up $7.40 or 2.33% --Would be new all-time high (Based on available data back to June 17, 1983) --Would be first new record closing high since Feb. 1, 2024,